Literature DB >> 22094932

Cognitive function and quality of life in ovarian cancer.

Denise D Correa1, Lisa M Hess.   

Abstract

OBJECTIVES: As advances in treatment have prolonged survival for many patients with ovarian cancer, there has been growing interest in assessing the adverse effects of disease and treatment. The aim of this study was to review the literature on cognitive function and quality of life (QOL) in this population.
METHODS: A review of published studies including formal assessment of neurocognitive functions and self-reported domains of quality of life, with an emphasis on cognitive function, was performed.
RESULTS: The small number of studies including formal evaluations of neurocognitive function suggests that many ovarian cancer patients experience cognitive difficulties associated with their disease and treatment. Several studies described declines in self-reported cognitive function that may impact QOL, but the results were not consistent across studies.
CONCLUSIONS: Adequately powered longitudinal studies including formal neurocognitive and QOL assessments are needed to advance our understanding of the incidence of cognitive dysfunction and its impact on functional ability and QOL in ovarian cancer patients. These research efforts may ultimately contribute to treatment decision-making through the identification of vulnerable patients, and to the development of appropriate intervention strategies to improve cognitive function and QOL.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22094932     DOI: 10.1016/j.ygyno.2011.11.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

Review 1.  Postoperative Cognitive Dysfunction: Minding the Gaps in Our Knowledge of a Common Postoperative Complication in the Elderly.

Authors:  Miles Berger; Jacob W Nadler; Jeffrey Browndyke; Niccolo Terrando; Vikram Ponnusamy; Harvey Jay Cohen; Heather E Whitson; Joseph P Mathew
Journal:  Anesthesiol Clin       Date:  2015-07-16

2.  Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial.

Authors:  Kevin T Liou; James C Root; Sheila N Garland; Jamie Green; Yuelin Li; Q Susan Li; Philip W Kantoff; Tim A Ahles; Jun J Mao
Journal:  Cancer       Date:  2020-04-22       Impact factor: 6.860

3.  Cognitive functioning and quality of life following chemotherapy in pre- and peri-menopausal women with breast cancer.

Authors:  Jennifer R Klemp; Jamie S Myers; Carol J Fabian; Bruce F Kimler; Qamar J Khan; Susan M Sereika; Annette L Stanton
Journal:  Support Care Cancer       Date:  2017-08-28       Impact factor: 3.603

4.  Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood.

Authors:  Tami John; Naomi Lomeli; Daniela A Bota
Journal:  Behav Brain Res       Date:  2016-11-13       Impact factor: 3.332

Review 5.  Prevalence, mechanisms, and management of cancer-related cognitive impairment.

Authors:  Michelle C Janelsins; Shelli R Kesler; Tim A Ahles; Gary R Morrow
Journal:  Int Rev Psychiatry       Date:  2014-02

6.  Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats.

Authors:  Naomi Lomeli; Kaijun Di; Jennifer Czerniawski; John F Guzowski; Daniela A Bota
Journal:  Free Radic Biol Med       Date:  2016-11-28       Impact factor: 7.376

Review 7.  Psychostimulants for cancer-related cognitive impairment in adult cancer survivors: a systematic review and meta-analysis.

Authors:  Nadia Miladi; Richi Dossa; Maman Joyce Dogba; Marie Immacula Fabienne Cléophat-Jolicoeur; Bruno Gagnon
Journal:  Support Care Cancer       Date:  2019-06-28       Impact factor: 3.603

Review 8.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

9.  Survivors of gynecologic malignancies: impact of treatment on health and well-being.

Authors:  Shannon N Westin; Charlotte C Sun; Celestine S Tung; Robin A Lacour; Larissa A Meyer; Diana L Urbauer; Michael M Frumovitz; Karen H Lu; Diane C Bodurka
Journal:  J Cancer Surviv       Date:  2015-08-06       Impact factor: 4.442

10.  Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.

Authors:  Lisa M Hess; Helen Q Huang; Alexandra L Hanlon; William R Robinson; Rhonda Johnson; Setsuko K Chambers; Robert S Mannel; Larry Puls; Susan A Davidson; Michael Method; Shashikant Lele; Laura Havrilesky; Tina Nelson; David S Alberts
Journal:  Gynecol Oncol       Date:  2015-10-09       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.